Hugel (145020) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
11 Feb, 2026Executive summary
Net sales in 4Q25 reached KRW 119.1bn, up 21.3% year-over-year, with full-year 2025 sales at KRW 425.1bn, a 14.0% increase year-over-year.
Operating profit for 4Q25 was KRW 58.6bn, up 26.2% year-over-year, and full-year operating profit rose 21.3% to KRW 201.6bn.
Net income for 4Q25 was KRW 36.8bn, down 11.0% year-over-year, while full-year net income was KRW 144.0bn, up 0.6% year-over-year.
Financial highlights
Gross profit margin improved to 80.8% in 4Q25, up 3.7 percentage points year-over-year.
SG&A expenses increased 28.5% year-over-year in 4Q25, reaching KRW 37.6bn.
Operating margin for 4Q25 was 49.2%, up 1.9 percentage points year-over-year.
Outlook and guidance
International sales momentum is strong, with significant growth in North & South America and EU & Others.
Latest events from Hugel
- H1 2024 revenue hit ₩169.7B, net income ₩59.7B, driven by global expansion and strong cash position.145020
Q2 202424 Jun 2026 - Operating profit surged 54.5% year-over-year, driven by strong toxin and global sales growth.145020
Q3 202424 Jun 2026 - Q1 2025 saw double-digit profit growth and global expansion, led by Asia Pacific sales.145020
Q1 202524 Jun 2026 - Double-digit sales growth led by botulinum toxin, derma cosmetics, and surging exports.145020
Q2 202524 Jun 2026 - KRW 305.98bn YTD revenue, lower profit, strong global growth, and robust Derma Cosmetics.145020
Q3 202524 Jun 2026 - Q1 2026 delivered strong growth, led by botulinum toxin and international sales, with robust cash reserves.145020
Q1 202622 Jun 2026 - Double-digit sales and profit growth in 4Q24, led by Toxin, Filler, and Cosmetics segments.145020
Q4 20247 May 2026 - Global expansion, strong financials, and innovation drive leadership in medical aesthetics.145020
J.P. Morgan HealthCare Conference 2025 presentation7 May 2026 - Targeting global leadership in aesthetics with innovative products and a hybrid U.S. sales model.145020
JP Morgan Healthcare Conference 2026 presentation7 May 2026